Abstract Number: 2628 • 2014 ACR/ARHP Annual Meeting
Risk of Cancer Is Not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Background/Purpose: Systemic immune dysregulation associated with chronic autoimmune diseases such as systemic lupus erythematosus (SLE) as well as immunomodulatory medications used for their treatment have…Abstract Number: 2627 • 2014 ACR/ARHP Annual Meeting
Comparison of Disease Characteristics and Organ Damage in Patients with Juvenile and Adult-Onset Systemic Lupus Erythematosus in Large Cohort from Turkey
Background/Purpose Systemic lupus erythematosus (SLE) is a multisystemic disease that may cause a broad spectrum of clinical and immunological manifestations. Age at onset has been…Abstract Number: 2626 • 2014 ACR/ARHP Annual Meeting
Relationship of Socio-Demographic and Disease Factors with Loss-to-Follow-up and Appointment Noncompliance in Indigent Patients with Systemic Lupus Erythematosus
Background/Purpose . The relationship of medical noncompliance with poor health outcomes has been described in chronic diseases, including systemic lupus erythematosus (SLE). These outcomes are…Abstract Number: 2625 • 2014 ACR/ARHP Annual Meeting
Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features
Background/Purpose: To measure work productivity and the related risk factors in patients with systemic lupus erythematosus (SLE) from Argentina. Methods: Employment status of 171 consecutive SLE…Abstract Number: 2624 • 2014 ACR/ARHP Annual Meeting
Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population
Background/Purpose Systemic lupus erythematosus (SLE) is a complex disease that is traditionally diagnosed and managed by specialists, typically rheumatologists. Higher SLE prevalence in racial/ethnic minorities…Abstract Number: 2623 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis
Background/Purpose: Currently, there is not a standard treatment algorithm for the management of Systemic Lupus Erythematosus (SLE); however, there are medications that may be considered…Abstract Number: 2622 • 2014 ACR/ARHP Annual Meeting
Systemic LUPUS Erythematosus in Spanish Males
Background/Purpose: To describe the demographic, clinical and immunological manifestations in male patients with Systemic Lupus Erythematosus(SLE) Methods: Patients diagnosed of SLE that were in the…Abstract Number: 2621 • 2014 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients' health-related quality of life (HRQOL). This cross-sectional study collected…Abstract Number: 2603 • 2014 ACR/ARHP Annual Meeting
Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study
Background/Purpose NSAIDs are the first-line therapy for spondyloarthritis (SpA) patients and are associated with the risk of kidney injury. Long-term NSAID use is known to…Abstract Number: 2604 • 2014 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort
Background/Purpose New ASAS criteria for axial spondyloarthritis (axSpA) have two entrances: the imaging and clinical arm (presence of HLA B27). The imaging arm allows classifying patients…Abstract Number: 2602 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Atherosclerosis in Patients with Spondyloarthritis without Clinically Evident Cardiovascular Disease Using Carotid Intima-Media Thickness
Background/Purpose AS and PsA patients without clinically evident cardiovascular disease have a high prevalence of subclinical cardiovascular disease in form of increased carotid intima-media thickness…Abstract Number: 2601 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab
Background/Purpose Serum biomarkers that can predict subsequent clinical or imaging outcomes would aid decision-making in the management of ankylosing spondylitis (AS). Using data from the…Abstract Number: 2600 • 2014 ACR/ARHP Annual Meeting
Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study
Background/Purpose: In ankylosing spondylitis (AS), gender-attributable differences have been reported with respect to clinical and radiographic outcome. However, longitudinal studies exploring gender-attributable differences in the…Abstract Number: 2599 • 2014 ACR/ARHP Annual Meeting
Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF
Background/Purpose The diagnosis of AxSpA is not easy and there are cases of overlap with fibromyalgia for example. Anti-TNF have been shown to have great…Abstract Number: 2598 • 2014 ACR/ARHP Annual Meeting
Disease Characteristics Associated with the Presence of Dactylitis in Patients with EARLY Spondyloarthritis: Results from Esperenza Cohort
Background/Purpose: Dactylitis is a typical manifestation in patients with SpA. Despite dactylitis has traditionally been related to the coexistence of psoriasis and peripheral arthritis, it…
ACR Meeting Abstracts